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Abstract
Maternal hypotension is a common sequala of spinal anesthesia used during cesarean
delivery. The current first line vasopressor used for treatment of maternal hypotension is
phenylephrine. Administration of phenylephrine can cause a physiologic decrease in
cardiac output that could contribute to adverse maternal or fetal outcomes. This
systematic review was conducted to investigate the use of norepinephrine as an
alternative vasopressor for the treatment of maternal hypotension. A database search was
conducted using electronic sources including CINAHL, MEDLINE, Google Scholar and
PubMed. Inclusion and exclusion criteria were used to narrow search results and the
Critical Appraisal Skills Program checklist was applied to critically appraise selected
randomized control trials. Five articles were selected to be included in this review. Key
outcomes were compared between studies and included incidence of maternal
hypotension, maternal cardiac output effects, incidence of bradycardia, incidence of
intraoperative nausea and vomiting, and fetal effects on Apgar score and umbilical cord
gases. Overall, norepinephrine was found to be of similar effectiveness to phenylephrine
for the treatment of maternal hypotension. When compared to phenylephrine,
norepinephrine was found to maintain maternal heart rate better, and had a lower
incidence of maternal bradycardia. No difference was found between intervention groups
in fetal Apgar scores and differences in fetal cord gases were varied between studies.
This systematic review found that norepinephrine has similar efficacy to phenylephrine in
ability to manage maternal hypotension with lower prevalence of bradycardia. Further
research is needed into the overall safety of norepinephrine before routine clinical
utilization.
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A Systematic Review of the Prophylactic Use of Phenylephrine Versus Norepinephrine
for The Treatment of Maternal Hypotension During Spinal Anesthesia for Cesarean
Delivery
Background/Statement of the Problem
Maternal hypotension, a common side effect of spinal anesthesia during cesarean
delivery, is a highly studied area due to its potential impact on both the mother and the
fetus. Rates of maternal hypotension as a consequence of spinal anesthesia performed
during elective cesarean sections are 70-80% without prophylactic pharmacological
management (Mercier, Augè, Hoffmann, Fisher & Le Gouez, 2013). Hypotension during
cesarean delivery can be potentially dangerous for both mother and fetus. A common
maternal side effect from untreated hypotension is nausea and vomiting, but side effects
may progress to cardiovascular collapse, loss of consciousness, pulmonary aspiration and
cardiac arrest. Maternal hypotension can also cause fetal complications such as
uteroplacental hypoperfusion and subsequent hypoxia, acidosis and neurological injury
(Chooi et al., 2017; Nagelhout, Elisha & Plaus, 2013).
Currently phenylephrine is the established first-line vasopressor for the treatment
and prevention of maternal hypotension (Nagelhout et al., 2013). Phenylephrine is a
potent direct-acting α1-adrenergic agonist; a pure vasoconstrictor. Due to its mechanism
of action, a reflexive decrease in heart rate (HR) and a consequent decrease in cardiac
output (CO) are common outcomes of phenylephrine administration (Ryu, Choi, Park, &
Kang, 2019). A 2010 study by Stewart et al. investigated the dose-dependent effects of
phenylephrine administration during spinal anesthesia for cesarean sections and found
marked decreases in maternal HR and CO. While the study did not show any noticeable
effects to the fetus, it was hypothesized that a decrease in CO may have a greater effect
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on a fetus during emergent situations where fetal pH may be more acidotic. In healthy
women, the transient decreases in HR and CO that accompany phenylephrine
administration appears to be accommodated without detrimental effect to the fetus.
However, there is concern that the use of phenylephrine could negatively impact
unhealthy mothers or fetuses with compromised health. For example, mothers with
impaired cardiac function could theoretically have greater decreases in HR and CO that
could impact fetal wellbeing. (Carvalho & Dyer, 2015). The growing evidence that
phenylephrine could cause detrimental effects to an at risk fetus has led to a renewed
interest into alternative vasopressors for the use of treating maternal hypotension.
Norepinephrine, an α1-adrenergic agonist and a mild β1-agonist, has been
suggested as a potential alternative to phenylephrine. When used prophylactically, it has
demonstrated the ability to maintain maternal blood pressure (BP) and increase both HR
and cardiac contractility, while preserving CO during spinal anesthesia (Ryu, Choi, Park,
& Kang, 2019). While investigation into the use of norepinephrine versus phenylephrine
is relatively new and ongoing, Ngan Kee, Lee, Ng, Tan, and Khaw’s 2015 study into
computer-controlled infusions of norepinephrine versus phenylephrine during spinal
anesthesia for cesarean delivery found norepinephrine effective for prophylactically
treating maternal hypotension.
The purpose of this paper is to conduct a systematic review to investigate the use
of norepinephrine versus phenylephrine for the treatment of maternal hypotension during
spinal anesthesia for cesarean delivery.
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Literature Review

Anesthesia during Cesarean Deliveries
Throughout history, there have been sporadic references to the use of cesarean
section as a method to save both mother and infants. Purportedly the birth of Julius
Caesar was via cesarean, and it is possible that this is the origin of the term “cesarean.” It
is also possible the term originates from the Latin word “caedare,” which translates to
cut, or from the term “caesones” which was historically the term applied to children born
through postmortem procedures. In its earliest form, the procedure was typically done on
a dead or dying mother to retrieve an infant and the rare reports of mother and baby
surviving are dubious. Despite medical innovations, the surgery remained a serious
procedure limited by patient’s pain and lack of anesthesia. It was not until in the
nineteenth century, when Queen Victoria utilized chloroform for the birth of two of her
children that the use of anesthesia as an adjunct to childbirth became popular and
practical (Sewell, 1993).
Today, cesarean deliveries are the most common major operating room procedure
performed in the United States (HCUP Fast Stats, 2019). Modern medical advancements
have increased the options available for anesthesia during obstetric procedures.
Generally, there are two main types of anesthesia: general anesthesia or central neuraxial
blocks. General anesthesia is the use of intravenous medications and/or inhaled
anesthetics to induce a state of unconsciousness, analgesia, and amnesia (Nagelhout, et
al., 2013). Central neuraxial blocks is the instillation of local anesthetic onto or near the
spinal cord. Central neuraxial blocks for cesarean deliveries are sub divided between
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spinal and epidural anesthesia, with spinal being typically used for non-emergent
cesarean deliveries if an epidural has not previously been placed for labor analgesia
(Miller & Pardo, 2011, p. 2344). Neuraxial blocks provide multiple benefits over general
anesthesia among patients who require anesthetic management for obstetric procedures.
Spinal and epidural anesthesia both have a lower risk for “nausea, vomiting, and urinary
retention; a reduced total opioid requirement; and increased mental alertness compared
with patients who have received general anesthesia alone” (Nagelhout et al., 2013, p.
1074). Other benefits include blunting of the stress response to pain or surgical stress, a
lower incidence of post-surgical emboli, a decrease in perioperative blood loss, and
improvements in respiratory function and cardiac stability (Nagelhout et al., 2013).
Ultimately the decision of neuraxial anesthesia versus general anesthesia is based on
multiple factors, including but not limited to: fetal condition, urgency of delivery,
maternal health and co-existing health problems, surgical concerns and maternal
preference (Miller & Pardo, 2011,p. 2344).
Spinal anesthesia for cesarean deliveries.
The most common form of spinal anesthesia for cesarean delivery is a single-shot
technique because of its reliability, ease of placement, and the quality of the sensory
blockade achieved (Lim et al., 2018). The procedure for placing a single dose of spinal
anesthesia is through the lumbar 3 and 4 vertebral disks. After the patient has been
prepped and the site numbed a 22- to 25-gauge needle is advanced between the spinous
processes. Three ligaments will be passed through before puncturing the dura and seating
the needle within the subarachnoid space where the medication of choice will be
administered (Nagelhout et al., 2013, p. 1080). While this method is only one technique
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of administration, the results of spinal anesthesia are the same; administration of
medication into the subarachnoid space.
Spinal anesthesia is commonly considered a superior option to general anesthesia
because it is thought to be more practical and safer for mother and fetus. One way that
fetal outcomes are assessed is through the Apgar assessment tool. It is a commonly used
score based off five categories; heart rate, respiratory rate, newborn muscle tone, reflex
irritability and skin coloring. Typically, the assessment is conducted at 1-minute and
again at the 5-minute mark post-birth (Nagelhout et al., 2013). A 2012 study by Solangi,
Khaskheli and Siddiqui compared general and spinal anesthesia on neonatal outcomes
found that both Apgar score and fetal pH were more affected by general anesthesia.
Unsatisfactory Apgar scores, as defined as a score less than 7, were observed in 25%
(n=20) of the neonates whose mothers received general versus the 2.5% (n=2) within the
spinal anesthesia group. The study also found that fetal pH levels were increasingly
acidotic in the general anesthesia neonatal group and concluded that spinal anesthesia is
favorable and preferred over general anesthesia (Solangi, Khaskheli & Siddiqui, 2012).
Maternal Hypotension.
Spinal anesthesia is a safe and frequently used practice; however, it is not without
predictable, undesirable side effects. Maternal hypotension, as defined as a twenty
percent drop in blood pressure from baseline pressure and/or a blood pressure less than
90-100mmHg, is the most common side effect (Miller & Pardo, 2011; Nagelhout et al.,
2013). As previously mentioned, the incidence of hypotension as a side effect of spinal
anesthesia during cesarean sections can be as high as 70-80% without prophylactic
pharmacologic management (Mercier et al., 2013). Several factors can explain the high
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rates and the severity of maternal hypotension. Hypotension is primarily caused by
hemodynamic changes due to spinal blockade and pharmacodynamic effects of local
anesthetics, yet these hemodynamic changes can be compounded by other factors such as
increased sensitivity to local anesthetics, the effects of pregnancy, and aortocaval
compression of the enlarged uterus (Mercier et al., 2013).
Spinal anesthesia uses local anesthetics to produce a sympathetic nerve block to
mitigate pain transmission. The blockade of the sympathetic nervous system can have
varying effects upon the cardiovascular system. These changes include: arterial
vasodilation, a reduction in systemic vascular resistance, and a decrease in venous return
with a resulting decrease in blood pressure (Nagelhout et al., 2013, p. 1083). Extensive
blocks may affect the innervation of cardioaccelerator fibers, found at T1-T4, which can
lead to a marked decrease in venous return and bradycardia. A dense T4 blockade is
required for cesarean section, so sympathectomy of the cardioaccelerators should be
anticipated. Resulting unopposed parasympathetic outflow can also affect the
compensatory reflexes to decreases in blood pressure such as baroreceptors, and volume
receptors (Miller & Pardo, 2011; Nagelhout et al., 2013).
Pharmacological effects of local anesthetics used in neuraxial blocks may also be
enhanced by physiologic changes because of pregnancy. As soon as the first trimester,
pregnant women become increasingly sensitive to local anesthetic pharmacological
affects. A study by Butterworth, Walker, and Lysak in 1990 found that median nerve
transmission was more susceptible to lidocaine block in pregnant women versus
nonpregnant women. It was hypothesized that changes in cellular mechanism could
increase susceptibility in pregnant women through changes to the Na+ channel where
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local anesthetics produce affect (Butterworth, Walker & Lysak, 1990). The increase
sensitivity to local anesthetics may increase block height and depth of sympathetic
blockade (Nagelhout et al, 2013, p. 1129).
Physiological changes that occur during pregnancy can also predispose patients to
hypotension. Pregnant women at term or near-term may be at risk for supine hypotension
syndrome, also known as aortocaval compression, which is caused by vena cava and
aorta compression by the gravid uterus. Aortocaval compression occurs mainly in the
supine position when the uterus lies vertically on the aorta and vena cava which run
concurrently along the spine. The partial occlusion of the great vessels can cause a
decrease in venous return, decreases in stroke volume and resulting decreases in cardiac
output (Nagelhout et al, 2013). There is an accompanying loss of arteriolar tone, which is
why despite numerous prophylactic options to prevent hypotension, vasopressors are the
most important treatment (Mercier et al, 2013). Physiological responses to compression
of the vena cava and aorta are increases in heart rate and vasoconstriction of lower
extremities, however the sympathectomy produced by spinal anesthesia may affect these
compensatory responses which can further contribute to hypotension (Nagelhout et al,
2013). Prevention of aortocaval compression is accomplished by left uterine
displacement, commonly accomplished by manual displacement, or by left lateral tilt,
either with pillow support or a 15-degree tilt of the operating room table. This
prophylactic treatment is universally recommended to prevent a decrease in blood
pressure and subsequent drop in venous return and collapse of cardiac output (Mercier et
al., 2013).
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Maternal and fetal effects of hypotension.
Maternal hypotension, if left untreated can progress to unconsciousness, total
cardiovascular collapse, and fetal compromise due to uteroplacental hypoperfusion
(Nagelhout et al., 2013 p 1143). Maternal effects of unmanaged hypotension can be mild;
nausea and vomiting, or progress to more severe side effects if left untreated. Severe side
effects could include altered levels of consciousness, aspiration into pulmonary airways,
decreased respiratory drive and eventual cardiac arrest (Patel, Shashank & Shivaramu,
2018). Adequate blood pressures are critical to maintain perfusion of vital organs such as
heart, brain, lungs, liver, kidneys and the uterus (Nagelhout et al., 2013).
A fetal side effect of maternal hypotension is uteroplacental hypoperfusion.
Maternal-fetal gas exchange is highly dependent on uterine and placental blood flow,
which is maintained by maternal cardiac output (Stewart et al., 2010). In normal adult
circulation, waste products of aerobic metabolism such as carbon dioxide are exhaled and
exchanged for oxygen, thus regulating the acid-base balance within the body. The fetus is
unable to exhale and is thus dependent on maternal circulation for the delivery of oxygen,
and after fetal metabolism the excretion of waste products (Fahey & King, 2010). Uterine
and placental hypoperfusion impacts fetal gas exchange which can create a state of
anaerobic metabolism within the fetus. Without oxygen exchange, hydrogen ions form
organic acids such as lactic acid which negatively impacts the fetal acid-base balance
(Nagelhout et al., 2013; Fahey & King, 2010). Normally adult pH is within the range of
7.35-7.45 while normal umbilical artery pH of newborns is 7.25-7.30 indicating fetal
homeostasis is maintained at a slightly more acidotic pH (Thorp, Sampson, Parisi &
Creasy, 1989).
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The natural progression of labor can produce transient periods of uteroplacental
hypoperfusion as the uterus contracts and interrupts normal blood circulation through the
placental barrier. Adaptive mechanisms for the fetus will maintain normal hemostasis
during these events, however when low perfusion states are prolonged such as during
maternal hypotension it can lead to fetal hypoxia. An increase in hydrogen ions from lack
of oxygen exchange will cause a decrease in fetal pH and respiratory acidosis.
Subsequently if hypoxemia and hypoxia continue, anaerobic metabolism will begin
producing lactic acid causing metabolic acidosis (Fahey & King, 2010). Post-partum
neonatal umbilical cord blood pH is routinely tested and is used as a predictor of fetal
outcomes. A 2019 study by Rimsza, Perez, Babbar, O’brien and Vricella investigated the
correlation between time of neuraxial placement to neonatal delivery and the effects of
umbilical arterial cord pH and found that maternal hypotension was one of the predictive
factors of decreasing neonatal pH levels. Cases with extended start times had lower
umbilical arterial pH along with lower venous pH and elevated pCO2 levels which is
consistent with fetal respiratory acidemia (Rimsza et al., 2019). Cases may have delayed
start times for numerous reasons, including but not limited to surgeon delay, operating
room availability, supply constraints, staffing issues or complications related to prepping
the patient for a procedure.
Interventions for Prevention and Treatment of Hypotension
Providers use a range of techniques to prevent and treat hypotension; intravenous
fluid administration, physical interventions such as uterine displacement or compression
devices, and pharmacological treatments (Choi et al., 2017). For several decades, fluid
therapy has been the traditional treatment for spinal anesthesia induced hypotension (Lee,
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George & Habib, 2017). Numerous studies have examined fluid therapy, studying the
type of fluids; crystalloid fluid versus colloid fluid, timing of the administration;
preloading versus co-loading in regard to timing of the block, and optimal quantities of
fluid to be administered. Although fluid administration will increase intravascular space,
thereby increasing cardiac output, it is thought that the fluid rapidly redistributes, and
rates of hypotension continue to be high (Lee, George & Habib, 2017). Currently, there is
no study that definitively shows that an ideal fluid type or amount will negate maternal
hypotension on its own.
As previously discussed, patient positioning can improve blood flow and is an
important nonpharmacological intervention for preventing hypotension. While uterine
displacement is widely accepted as a nonpharmaceutical intervention, manual
displacement of the uterus by the provider appears to have superior efficacy when
compared to left lateral tilt of the patients hips or operating room table (Choi et al., 2017).
Other techniques such as lower leg compression or elevation of the legs do not appear to
be overtly effective, however few studies have examined these techniques and those that
did had small cohorts (Choi et al., 2017).
Vasopressors have been found to be the most important intervention in the
treatment of maternal hypotension (Mercier et al., 2013). Ephedrine, a synthetic indirectacting sympathomimetic that has both alpha- and beta-adrenergic receptors, was
historically the vasopressor of choice (Nagelhout et al, 2013). A shift away from
ephedrine occurred after increasing evidence showed that ephedrine crosses the placenta
barrier with an associated decrease in umbilical arterial pH and base excess (Ngan Kee,
Shaw, Tan, Ng, & Karmaker, 2009). Phenylephrine is currently the established
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vasopressor for treatment and prevention of maternal hypotension (Nagelhout et al.,
2013). Recently, evidence has shown that phenylephrine has the propensity to decrease
maternal heart rate and cardiac output which could potentially have deleterious effects to
the fetus (Stewart et al., 2010). As a result, there has been a renewed interest in
alternative vasopressors such as norepinephrine to treat maternal hypotension.
Phenylephrine
Phenylephrine (Neo-synephrine) is a direct-acting sympathomimetic amine that
has α1-adrenergic agonist with minimal to no beta-adrenergic affinity. It has FDAapproval for the use of treatment for clinically significant hypotension from vasodilation,
such as from neuraxial anesthesia (Richards & Maani, 2019). It is an ideal vasopressor
because it has a quick onset, short duration, and has expected dose-dependent responses.
Intravenous (IV) phenylephrine has potent vasoconstriction properties which can increase
preload, systemic vascular resistance and afterload. However, phenylephrine’s
stimulation of alpha-adrenergic receptors only can lead to baroreceptor-mediated reflex
bradycardia (Richards & Maani, 2019). This decrease in heart rate and consequent
decrease in cardiac output raises concern over uteroplacental perfusion side effects
(Carvalho & Dyer, 2015).
Norepinephrine
Norepinephrine is a sympathomimetic amine which primarily works as an α1adrenergic agonist with β1-agonist with mild to no effect on β2 or α2 receptors.
Structurally it is identical to epinephrine, but a lack of methyl group on its nitrogen atom
affects its site of action. It is FDA-approved for blood pressure control during acute
hypotensive states and is commonly the first line agent for treating hypotension during
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septic shock (Smith & Maani, 2019). Norepinephrine has strong vasoconstricting
properties with less potent direct inotropic abilities and minimal chronotropic effects
which is beneficial for patients whose heart rate stimulation is unwarranted (Overgaard &
Džavik, 2008). Norepinephrine primarily increases both systolic and diastolic blood
pressures, with an increase to pulse pressure and a minimal net impact on patients’
cardiac outputs (Overgaard & Džavik, 2008).
Due to norepinephrine’s strong vasoconstricting properties, concern exists for
potentially severe complications if administered through a peripheral venous catheter.
Complications include extravasation, thrombophlebitis, localized cellulites, and tissue
necrosis (Nagelhout et al., 2013). A recent observational study investigated the
complications from vasopressor administration via peripheral venous catheters.
Significant morbidity was not established, and the authors found that administration of
norepinephrine through peripheral IVs for a median duration of 13 hours [interquartile
range of 6.5-31.5 hours] had a low rate (5.5%) of minor complications which did not
require any intervention (Medlej et al., 2017). It is still recommended that instillation of
norepinephrine should be through a large-bore peripheral catheter, ideally in the
antecubital vein or through a central venous catheter.
The use of norepinephrine as an alternative to phenylephrine for the treatment of
maternal hypotension is a relatively novel idea. In the United States norepinephrine’s
area of use is typically the intensive care unit or in cardiac anesthesia while
phenylephrine is a commonly used medication readily available in the operating room.
The possible future use of norepinephrine could be met with logistical and culture
resistance (Carvalho & Dyer, 2015). Despite possible resistance, it is worth investigating
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norepinephrine as a potential alternative to phenylephrine due to its lower incidence of
bradycardia and minimal decreases in cardiac output.
Next the frameworks used to guide this review will be discussed.
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Theoretical Framework
The PRISMA framework was used as the theoretical framework for this
systematic review. The Preferred Reporting Items for Systematic Reviews and MetaAnalyses (PRIMSA) Statement was developed from the QUOROM Statement (Quality of
Reporting of Meta-Analyses) which was developed in 1996 (Moher, Liberarti, Tetzlaff,
Altman, & The PRISMA group, 2009). The updated and revised PRISMA Statement
addresses multiple advances that have been made in the science among systematic
reviews (Moher et al., 2009). The goal of PRISMA is to aid investigators in their
assessment of systematic reviews and aid in the writing of a systematic review using a
flow diagram and checklist. The use of PRISMA ensures increased transparency among
systematic reviews and aims to minimize potential bias from study selection.
The PRISMA Statement includes a 27-item checklist (Appendix A) and includes
seven major categories: title, abstract, introduction, methods, results, discussion, and
funding. Subheadings within the major categories go on to describe the checklist item in
further detail. In addition to the checklist, The PRISMA Statement also consists of a
four-phase flow diagram (Figure 1), illustrated on the next page. The flow diagram helps
guide the identification, screening, eligibility and inclusion or exclusion of research
studies (Moher et al., 2009). The comparative use of norephedrine versus phenylephrine
to prevent or in treatment of maternal hypotension is a recent idea with limited research.
The current, available randomized controlled trials were assessed utilizing the PRIMSA
checklist to aid in inclusion and exclusion of randomized control trials.
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Figure 1. PRISMA 2009 Flowchart (Moher et al., 2009)

16

Method
Purpose
The purpose of this paper was to conduct a systematic review to investigate the
use of norepinephrine versus phenylephrine for the treatment of maternal hypotension
during spinal anesthesia for cesarean delivery.
Inclusion and Exclusion Criteria
Inclusion criteria was randomized control trials that investigated the use of
phenylephrine and/or norepinephrine for the treatment of maternal hypotension during
spinal anesthesia for cesarean delivery. Studies published between January 2009 to
December 2019 that include women 18-55 years of age undergoing scheduled or
emergent cesarean delivery were included. Women with past medical histories of preeclampsia were also included. Outcomes included were maternal hemodynamics; HR,
CO, BP, and fetal outcomes; Apgar score, pH and umbilical blood gases. Exclusion
criteria was studies published before 2009 and those not in the English language, and
studies involving non-cesarean delivery use of phenylephrine or norepinephrine.
Search Strategy
The search was conducted using the databases CINAHL, MEDLINE, Google
Scholar and PubMed. The terms searched were Phenylephrine, Norepinephrine, spinal
anesthesia, maternal hypotension, low blood pressure, cesarean delivery and/or c-section,
complications, fetal compromise and randomized control trial. The planned search was
limited to the above-mentioned inclusion criteria. The PRISMA flowchart and checklist
were used to evaluate and validate selected randomized control trials.
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Data Collection
Data collected through the above methods was organized in a data collection
table, depicted below (Table 1). The study characteristics included in each table were the
studies purpose, sample/setting, anesthesia provided, interventions, outcomes and any
limitations within the study. Tables were completed for each randomized control trial
selected for this study and analyzed for relevant data (Appendix C).
Table 1
Data Collection Table
Citation:
Purpose &
Sample/Setting

Anesthesia

Intervention

Outcomes

Limitations

Critical Appraisal
The Critical Appraisal Skills Program (CASP) checklist was utilized to critically
appraise the randomized control trials selected for this systematic review. The 11-item
CASP checklist was utilized in evaluating the results of each randomized control trial and
identifying any limitations or biases within the studies. CASP considers three issues
when considering and appraising a trail: Are the results valid, what are the results, and
will the results help locally? The first three questions are progressive and if the answer is
“yes” it is suggested to proceed to the remaining questions. Most of the remaining
questions may be answered with a “yes,” “no,” or “can’t tell (CASP, 2018).” The CASP
checklist was completed for each randomized control trial selected for this systematic
review (Appendix C).
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Figure 2. CASP Checklist (CASP, 2018)

Data Synthesis
A data synthesis table was created to synthesize data extracted from the five
selected randomized control trails. A cross study analysis was performed to identify
effects of norepinephrine versus phenylephrine for the treatment of maternal hypotension
during spinal anesthesia for cesarean delivery. The data was organized into a table with
the focus on effects on maternal hypotension, incidence of bradycardia, effects on cardiac
output, incidence of nausea and vomiting, neonatal Apgar scores and effects on umbilical
cord gases. The data synthesis table (Table 2) was used for cross-study analysis and
results will be discussed in detail in the results section of this systematic review.
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Table 2
Data Synthesis Table
Author,
Year

ASA
Classification
& Patient
Characteristics

Incidence of
Maternal
Hypotension

Maternal
Cardiac
Output

Next, the results section will be discussed.

Incidence
of
Bradycardia

Incidence of
intraoperative
nausea/vomiting

Neonatal
Apgar
Scores

Umbilical
Cord
Gases
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Results
A database search was conducted and a total of 15 non-duplicate citations were
screened. The completed PRISMA diagram shows the elimination of citations (Figure 3).
The titles and abstracts were reviewed for inclusion or exclusion criteria and 7 articles
were excluded based off preliminary analysis. One article was excluded after data
extraction. The five remaining articles were reviewed completely, and inclusion and
exclusion criteria were again applied with no articles needing to be eliminated. The five
articles were included in this systematic review.

Figure 3. Completed PRISMA flow diagram demonstrating article screening, inclusion or
exclusion and final results.

21

Individual Study Analysis
In 2015, Ngan Kee et al. published the landmark RESPOND study, a randomized
control study evaluating the use of phenylephrine verses norepinephrine for the
maintenance of blood pressure after spinal anesthesia for cesarean delivery (Appendix B1). The study compared the use of computer-controlled closed loop infusions of the study
drugs for the maintenance of maternal blood pressure. The primary outcomes assessed
were maternal heart rate (HR) and cardiac output (CO). Secondary outcomes were
neonatal outcomes and assessment of umbilical cord gases.
Sample size was calculated based on the authors previously published and
unpublished studies which evaluated hemodynamic data from obstetric patients. A
sample size of 47 patients per group was calculated to have a larger than 90% power to
detect a 20% change in CO between study groups five minutes after intrathecal injection
with an α error probability of 0.05. Polynomial data was analyzed using the KolmogorovSmirnov test and cross analyzed using Student t test or the Mann-Whitney U test.
Nominal data was assessed using the chi-square test of the Fisher exact test. Values for
CO, stroke volume (SV), and systemic vascular resistance (SVR) were measured
noninvasively using suprasternal Doppler and values were normalized to percentage of
baseline. Due to the variable times to complete measurements for HR and systolic blood
pressure (SBP) data was grouped according to chronological recording.
Initially 104 women were recruited into the Ngan Kee et al., (2015) study.
Exclusion data was applied and 49 patients were randomized into the norepinephrine
group (group N) and 52 patients into the phenylephrine group (group P). Patients
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received standardized treatments upon study admittance and patient characteristics and
surgical times were comparable between groups. All patients were fasted the night prior
to the c-section and received prophylactic antacid medications. On arrival to the
operating room baseline hemodynamics were recorded with pulse oximetry,
electrocardiography, and non-invasive blood pressure with mean arterial blood pressures
(MAP) being calculated from the latter. CO, SV, and SVR were also obtained and
repeated three times for baseline value. All hemodynamics were measured by an
experienced operator who was blinded to patient group assignment.
After a large-bore intravenous cannula was placed all patients received
standardized spinal anesthesia in the right lateral position. Infusion of study drugs was
started at the time of intrathecal injection. A solution of either norepinephrine 5mcg/ml or
phenylephrine 100 mcg/ml was administered from prepared 50-mL syringes that were
labeled “study drug.” The concentration of norepinephrine 5mcg/mL or phenylephrine
100 mcg/mL were thought to be equipotent at a ratio of 20:1 based on previous
comparative studies done by Sjöberg, Andersson, and Steen (1989). The study drug
administration was regulated using a computer-controlled closed-loop feedback system
based off the patients SBP which was set to cycle every 1 minute. The infusions were
initially started at 30mL/hour and after completion of the first SBP measurement the rate
was adjusted based off the computer algorithm. Administration rates were limited to 0-60
mL/hour (range of 0-5 mcg/minute of norepinephrine and 0-100 mcg/minute of
phenylephrine) and defaulted to a rate of 0 mL/hour if the patients HR was <50 beats per
minute (bpm). Endpoint was set at the time of neonatal delivery.
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Serial hemodynamics were monitored throughout the cesarean delivery; BP and
HR were set for 1-minute cycle times, while CO, SV, and SVR were measured in 5minute intervals. Of note, one patient from group N required supplemental oxygen for a
pulse oximeter reading <95%. After delivery, the neonate’s Apgar score was assessed by
a midwife at the 1-minute and 5-minute post-delivery mark. Samples of umbilical arterial
(UA) and umbilical venous (UV) blood were collected from a double-clamped stretch of
the umbilical cord. Samples with insufficient blood quantity or equipment failure were
accounted for within the study.
The study outcome concluded that maternal SBP was maintained similarly
between study groups, but norepinephrine use correlated with a greater HR and CO with
a lower SVR. It found that CO at the five-minute point was higher in group N versus
group P, with a P value of 0.004. SVR was lower in the group N when compared to group
P (P<0.001). Group N rates of bradycardia (defined as a HR <60 bpm) were less then
group P (18.4% vs 55.8%, P<0.001). There was no difference in SV between groups
(P=0.44). Ngan Kee et al., attributed the greater CO in group N to be primarily related to
the lower incidence of bradycardia since CO is based off a patients HR and SV. UV pH
and UV oxygen content were higher in group N which the authors attributed to the
greater placental blood flow theoretically from the increase in CO. Neonatal outcomes
were found to be otherwise similar between groups. The authors concluded that
norepinephrine and phenylephrine have similar efficacy for the maintenance of blood
pressure following spinal anesthesia for cesarean delivery, but norepinephrine maintained
greater maternal HR and CO. The authors suggested further studies would be warranted
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to investigate norepinephrine and its safety for use among obstetric patients, modes of
administration, and relative potency of norepinephrine versus phenylephrine.
The 2019 study by Wang, Mao, Liu, Xu & Yang, compared the efficacy and
safety of bolus dose norepinephrine, phenylephrine and ephedrine for the treatment of
hypotension during cesarean delivery under spinal anesthesia for parturients with
preeclampsia (Appendix B-2). The primary outcome measured was maternal SBP and
HR. Secondary outcomes assessed were incidence of tachycardia, bradycardia, and
hypertension. The amount of vasopressor required, number of hypotensive episodes,
maternal side effects and neonatal outcomes were also analyzed.
Wang et al., enrolled parturients between January and June of 2018 at a hospital
in Nanjing, China. Sample size was calculated based off a pilot study that examined the
rates of tachycardia with the use of norepinephrine or ephedrine treating parturients with
preeclampsia. A minimum of 49 cases per group was calculated to detect a statistically
significant difference in rates of tachycardia between groups. The sample size was
increased to 55 patients per group to account for possible drop out. Univariate data was
analyzed using D’Agostino-Pearson omnibus normality test and one-way analysis of
variance (ANOVA) and then by a two-sample t-test or Mann-Whitney test. Nominal data
was analyzed using a chi-squared test or Fisher’s exact test. A p-value of <0.05 was
considered to be statistically significant.
A total of 368 women were initially recruited into the study. After inclusion and
exclusion criteria was applied 315 patients were randomized into the three study groups.
Only patients who had successful spinal anesthesia and those who developed hypotension
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were included in the final analysis. Final enrolled participants included 56 patients
allocated to the norepinephrine group (group N), 55 patients to the phenylephrine (group
P) and 55 patients to the ephedrine (group E) group. Inclusion criteria was American
Society of Anesthesiologist (ASA) status I-II, singleton pregnancy scheduled for spinal
anesthesia and included a diagnosis of pre-eclampsia. Pre-eclampsia was defined as at
least two BP readings of ≥140/90 mmHg in a four-hour interval, with a 24-hour
proteinuria of ≥300 mg or ≥1+ with a dipstick. Parturients with severe pre-eclampsia
were also included in the study. Severe pre-eclampsia was defined as a BP reading of
≥160/110 with any of the following comorbidities; low platelets, cerebral or visual
disturbances, pulmonary edema, altered liver function and impairment of renal function.
Patients received standardized treatment regarding anesthesia and study
medication administration. Upon entering the operating room, participants were
positioned in supine, left uterine displacement position and three consecutive readings of
BP, HR, and pulse oximetry were taken for baseline value. An independent researcher
recorded all maternal hemodynamic values; BP and HR were recorded every minute from
intrathecal anesthesia instillation until neonatal delivery. Patients were positioned in the
left lateral position and received an intrathecal injection of 2.0-2.2 ml of hyperbaric
bupivacaine 0.5%. Immediately following injection, patients were returned to the left
uterine displacement supine position and received Ringer’s lactate hydration at a
maximum rate of 10ml/kg. Hypotension following intrathecal injection was defined as an
SBP <80% of patients baseline readings and treatment was administration of the selected
study drug. Based off group assignment, patients received either norepinephrine 4mcg,
phenylephrine 50mcg, or ephedrine 4mg. Atropine 0.5mg intravenously was injected for
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bradycardia, defined as a HR of <60 bpm. The study endpoint was delivery of the
neonate. After delivery umbilical artery blood was collected from a double-clamped cord
and a pediatrician evaluated the neonate using the Apgar scoring system at one minute
and five minutes. Blood gases that could not be accounted for due to insufficient blood
samples or equipment failure were accounted for within the groups.
Due to the diagnosis of pre-eclampsia, multiple patients within the study groups
were receiving antihypertensive treatments (group N n=42, group P n=40, group E n=40).
Ten women in group N, twelve women in group P, and eight women in group E were
diagnosed with severe pre-eclampsia. Within those diagnosed with severe pre-eclampsia,
six in group N, five in group N, and five in group E received magnesium sulfate as a
prophylaxis against seizures, a risk of severe pre-eclampsia. Of note, not included in the
study was the type of antihypertensive patients were prescribed or if those medications
could have affected study medications administered.
The outcome of Wang et al., 2019 study into the efficacy and safety of bolus
norepinephrine, phenylephrine, and ephedrine concluded that overall all three
medications were effective in the treatment of spinal hypotension in pre-eclamptic
women (Appendix D). However, group N was found to be superior to other study
medications at maintaining HR. Group N had less incidence of tachycardia (defined as a
HR >120 bpm) when compared to group E (16.1% vs 36.4%; P=<0.05) and less
incidence of bradycardia when compared to group P (3.6% vs 21.8%; P=<0.004). No
statistical difference was found between groups in the number of hypotensive episodes,
the number of boluses required, or the incidence of hypertensive episodes. Incidence of
intraoperative nausea and vomiting (IONV) was found to be lower in group N (5.4%)
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versus group E (20%) (P=0.02). Neonatal Apgar scores were similar among groups and
no neonate had an Apgar score of <9 at the five-minute assessment. Fetal UA pH was
higher in group N versus group E (7.32 ±0.02 vs 7.31 ±0.031; P=0.006). Among the
groups, no neonate had fetal acidosis, defined as an UA pH <7.20. UA lactate was also
found to be lower in group N (1.3±0.3) verses group E (1.8±0.5) (P=<0.001). No
statistically significant differences were found in the UA blood gases between groups N
and P. The authors concluded that while norepinephrine had similar efficacy for the
maintenance of SBP when compared to the other study drugs, it had an improved
maternal safety profile when compared to phenylephrine. They also stated that
norepinephrine had an improved maternal and neonatal safety profile when compared
with ephedrine.
The 2017 study by Vallejo et al., compared the use of prophylactic infusions of
phenylephrine versus norepinephrine for the maintenance of systolic blood pressure
during cesarean delivery under spinal anesthesia (Appendix B-3). The primary outcome
measured was the number and total dose of rescue boluses needed to maintain SBP in
addition to the study drug infusion. Secondary outcomes measured were maternal
hemodynamics; HR, CO, cardiac index (CI), SV, and SVR. Fetal outcomes such as
Apgar score at 1 minute and 5 minute and umbilical cord blood gases were also analyzed
of obtained as part of the neonate’s routine care.
The Vallejo et al., study enrolled 85 patients into their study between August
2014 and August 2015. The authors calculated sample size based off a local pilot study
which indicated that 35 parturients were required per group to detect a decrease to 10% in
the rates of maternal hypotension at the 0.05 significance level with 80% power. Overall
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study size was increased to 85 patients to account for dropout. A two-sample Z-test was
utilized to analyze the difference between groups in the number of patients requiring at
least one rescue bolus. Nominal data for secondary outcomes was analyzed using the chisquared test. Hemodynamic parameters and trends were analyzed using multivariate
analysis of variance (MANOVA). A P value of <0.05 was considered to be significant.
Patients were randomized to two treatment groups using a computer-generated
table. Group one (group P, n=38) received a fixed rate infusion of 0.1mcg/kg/min
phenylephrine while group two (group N, n=39) received 0.05 mcg/kg/min
norepinephrine also at a fixed rate. Inclusion criteria included an ASA status of <III, >36week singleton pregnancy with a BMI <40kg/m2. Patient characteristics and
demographics were similar between both study groups. All patients were accounted for at
the conclusion of the study and once enrolled patients received standardized treatment.
All patients had preoperative SBP and HR measured three times consecutively
and averaged for a baseline. Prior to entering the operating room study participants
received 500mL of lactated Ringers solution intravenously. Upon entering the operating
room, patients received a standardized spinal anesthetic in the sitting position consisting
of hyperbaric bupivacaine 12-15mg with an opioid adjunct of fentanyl 20mcg and
preservative-free morphine 0.2mg intrathecally. The selected study drug, which was
made aware to the anesthesia provider upon patient arrival, was started at the time of
intrathecal injection. Hypotension was defined as a decrease below 100% of baseline and
was treated with a rescue bolus of 100 mcg phenylephrine. Bradycardia as defined as a
HR <60 bpm was treated by infusion discontinuation and if compounded with
hypotension was treated with a rescue bolus of 5 mg of ephedrine. Infusions were held
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for any episodes of hypertension, as defined by an SBP >120% of baseline.
Hemodynamics were continuously recorded using a non-invasive hemodynamic monitor.
The study endpoint was at the point of transfer of care back to labor and delivery
postoperatively.
The study by Vallejo et al., concluded that prophylactic fixed-rate infusions of
norepinephrine were efficacious for the prevention of hypotension after spinal anesthesia
during cesarean delivery. The study found no difference between groups in study drug
infusion length, incidence of bradycardia, or non-invasive hemodynamic parameters (HR
P=0.17, CO P=0.5, SVR P=0.54). The number of patients who received ≥1 rescue bolus
of phenylephrine was similar between groups (Group P 52.6% vs group N 46.5%,
P=0.58). However, the use of ≥1 bolus of rescue dose ephedrine was higher in group P
(23.7%) in comparison to group N (2.3%) (P<0.01). Overall incidence of IONV was
similar between groups however the incidence of emesis was greater in group P (26.3%)
than in group N (1.63%) (P<0.001). No statistically significant difference was found in
fetal Apgar scores <7 at 1 minute (P=0.82) or 5 minutes (P=0.48) and UV pH were
similar between groups (P=0.42). The authors concluded that norepinephrine infusions
can be considered as an alternative to phenylephrine however future research is required
to analyze its overall safety.
The 2018 randomized control trial by Sharkey et al., investigated the use of bolus
dose phenylephrine verses norepinephrine to prevent and treat hypotension during
cesarean delivery (Appendix B-4). The primary outcome assessed was rate of maternal
bradycardia as defined as a HR <50 bpm. Secondary outcomes assessed included the
incidence of maternal hypotension or hypertension, incidence of tachycardia, and
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episodes of nausea and/or vomiting. Fetal outcomes were also assessed through umbilical
gas analysis, and fetal Apgar scores.
Study sample size was calculated based on two previously conducted studies by
Sharkley et al., research group. A sample size of 112 total participants was estimated to
achieve 80% power to detect a 70% decrease in the episodes of bradycardia in each group
with a significance level of 0.05. The goal of 56 participants per group accounted for an
anticipated 5% withdrawal rate. Data for the primary outcome, bradycardia, was analyzed
using the

2

test. Secondary outcomes were compared using the

2

test or the Fisher

exact test for categorical variables, and the Student t test or Wilcoxon rank sum test,
when appropriate for continuous variables. A P value of <0.05 was considered to be
statistically significant.
Between January 3, 2017 and April 17, 2017 Sharkey et al., enrolled 112 eligible
parturients to be placed evenly into two treatment groups. Patients were randomized into
their respective treatment groups using computer generated block randomizations. Group
one, (group P, n=56) received a standard dose of phenylephrine 100mcg while group two
(group N, n=56) received a standard dose of norepinephrine 6mcg. The study drugs were
administered manually by an anesthesia provider, who was blinded to group allocation, to
prophylactically prevent or treat hypotension as defined as an SBP <80% baseline value.
Inclusion criteria for study participants included an ASA status of ≤III, singleton term
pregnancy with a weight between 50-100kg. Patients received standardized treatments
upon study admittance and patient characteristics were similar between the two treatment
groups. All patients had preoperative SBP and HR measured three times one minute apart
for baseline values. Upon entering the operating room, patients were connected to
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standard monitoring equipment and positioned in the sitting position. Standardized spinal
anesthesia was administered in the L3/4 interspace as identified by ultrasound.
Immediately after intrathecal injection patients were coloaded with 10mL/kg (maximum
of 1 liter) of lactated Ringer’s infusion via pressure bag infusion. Patients were positioned
left lateral tilt and SBP, HR and pulse oximetry were monitored every 1 minute for the
duration of the study which continued from the time of intrathecal injection to the
delivery of the fetus. Selected study drugs could be administered as often as one minute
prophylactically or for any episode of hypotension. Rescue boluses of ephedrine 10mg
were administered for any hypotensive episodes coinciding with a HR <60 or for any
hypotensive episodes lasting more than 2 consecutive BP readings regardless of study
drug administration.
The study outcome by Sharkey et al., concluded that intermittent bolus doses of
norepinephrine to prevent hypotension during cesarean delivery had a lower incidence of
bradycardia when compared to bolus dose phenylephrine (Appendix D). The rate of
bradycardia was lower in group N when compared to Group P (10.9% vs. 37.5%;
P=<0.001) which implied a relative reduction of 71%. Using the

2

test to analyze the

data, it was found that patients in group P had a higher risk of having multiple episodes of
bradycardia when compared to group N (P=0.008). While there was no statistical
difference between groups regarding rates of hypotension (P=0.9), the incidence of
patients requiring rescue boluses of ephedrine for 2 consecutive hypotensive SBP
readings was higher among group P (21.4%) verses group N (7.2%) (P<0.3). Rates of
nausea and vomiting were similar between groups (P=0.57, P=0.17 respectively). Fetal
outcomes were comparable between groups; no Apgar score was <7 at 1-minute or 5-
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minute assessments for either group. There was no statistical difference in umbilical
arterial or venous blood gases between the two groups. The authors concluded that
phenylephrine and norepinephrine had similar efficacy for the maintenance of maternal
blood pressure during spinal anesthesia for cesarean delivery, however norepinephrine
had a lower incidence of bradycardia.
The 2019 randomized control trial by Mohta, Garg, Chilkoi and Malhotra
investigated the use of phenylephrine verses norepinephrine for the treatment of
hypotension following spinal anesthesia for caesarean section (Appendix B-5). The
primary outcome measured was rates of maternal bradycardia following study drug
administration. Secondary outcomes were overall blood pressure changes, study drug
requirements, maternal complications, and neonatal outcomes.
Mohta et al., recruited 90 parturients between December 2016 to January 2018.
All patients who entered the trial were properly accounted for throughout the study.
Inclusion criteria was a singleton, uncomplicated, term pregnancy. Participants were
randomized into group allotments via a computer-generated random number table and
investigators, anesthesia providers and patients were blinded to group allotment. Study
recruitment size was based off a previously done study by Mohta et al., which found that
a sample size of 45 patients per group would show a clinically significant 60% decrease
in incidence of bradycardia with norepinephrine with a power of 80% at a 0.05
significance level. Primary study data was analyzed with the Fisher’s exact test.
Hemodynamic and other parameters were tested by the Shapiro-Wilk test as appropriate.
Normally distributed variables were analyzed using the unpaired students t-test. Nonnormal variables, such as episodes of hypotension, vasopressor boluses, neonatal Apgar
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scores were analyzed with the Mann Whitney U-test and a p value of <0.05 was
considered to be significant. SBP and HR were compared with a linear mixed model and
a p value of <0.01 was considered significant.
Women enrolled were randomized into two study groups for the Mohta et al.,
2019 study. Group one (group P, n=45) received a bolus of 100 mcg of phenylephrine IV
for any hypotensive SBP episode, while group two (group N, n=45) received a 5 mcg
bolus of norepinephrine. Hypotension was defined as a decrease of ≥20% from SBP
baseline or an SBP <100 mmHg. Baseline SBP and HR were obtained upon entering the
operating room and based off an average of three consecutive recordings. All participant
received Ringer’s lactate solution at a rate of 15 ml/kg via IV which was initiated upon
entering the operating room. Standard spinal anesthesia was performed in the sitting
position and after administration patients were positioned left uterine tilt supine position.
All patients received 40% oxygen via facemask until fetal delivery. Patients HR and BP
were monitored every minute starting after spinal administration and study end point was
set at delivery. Patients received the selected study drug for any episode of hypotension
as previously defined. Bradycardia was defined as a HR of <60 bpm and 0.6 mg IV of
atropine could be administered for any episode of bradycardia combined with
hypotension or for an absolute HR <45 bpm. Neonatal Apgar scores were assessed at 1
minute and 5 minutes post-delivery. UA and UV blood gases were sampled prior to the
baby’s first breath via a double clamped segment of umbilical cord.
Finally, Mohta et al., concluded that there was no significant difference in the
rates of maternal bradycardia when using phenylephrine or norepinephrine for the
treatment of hypotension after spinal anesthesia. Incidence of bradycardia was
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comparable between the group P (37.8%) and group N (22.2%) (P=0.167). There was no
statistically significant difference between groups in the incidence of hypotensive
episodes (P=0.06). However, the total number of vasopressor boluses required to treat
hypotensive episodes was higher in group P than group N (P=0.01). Rates of maternal
nausea, vomiting and dizziness were comparable between the two groups (P=1.00).
Umbilical blood gases showed higher levels of UA pH in group P (mean 7.29) versus
group N (7.25) (P=0.03). Fetal levels of bicarbonate and base excess in UA and UV
samples were also higher among group P than group N. No significant difference was
found between groups regarding Apgar scores at 1 minute or 5 minutes. The study
concluded that 100 mcg of phenylephrine and 5 mcg of norepinephrine were similar in
their ability to treat hypotension after spinal anesthesia and had no significant difference
in incidence of bradycardia. Due to the differences found in umbilical blood gases, the
authors concluded that more research is warranted into placental transfer and metabolic
effects of norepinephrine.
Cross Study Analysis
The data synthesis table (Appendix D) demonstrates the key outcomes across the
five studies. All five studies were current, randomized control trials that directly
compared phenylephrine to norepinephrine, apart from Wang et al., which also compared
ephedrine. The method of medication administration varied between studies and included
closed loop computer administration, bolus dose administration, or fixed rate infusions.
All of the studies investigated the incidence of maternal hypotension and incidence of
bradycardia. Maternal cardiac output effects were investigated in two of the five studies;
Ngan Kee et al., 2015, and Vallejo et al., 2017.
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Patient characteristics and treatment were comparative throughout the studies
except for Wang et al., 2019 which enrolled women with a diagnosis of preeclampsia. All
patients included were ASA I-III, singleton, >36-week pregnancies who received spinal
anesthesia for scheduled cesarean delivery. Selected spinal anesthesia was single-dose
hyperbaric bupivacaine administered into the lumber space. There were variations among
the studies regarding the use of narcotics; morphine and/or fentanyl included in the
intrathecal anesthesia. Parturients were hydrated with either Hartmann’s solution or
Ringer’s Lactate with dosing ranging from 10ml/kg to 2L cumulative.
Among the five studies, hemodynamics were monitored throughout the surgical
period using a variaty of noninvasive monitors. The definitions of hypotension varied
between trials. Hypotension was defined as an SBP <80% of baseline in the majority of
studies with the exception of Vallejo et al., 2017 which defined it as a decrease of
<100% of baseline, and Mohta et al., 2019 defined it as a decrease of ≥20% or an
absolute value of <100 mmHg. None of the studies found a statistical difference between
the rates of hypotensive episodes between the norepinephrine or phenylephrine treatment
groups. Cardiac output was monitored in Ngan Kee et al., 2015, and Vallejo et al., 2017.
Data was conflicting between the two studies, with Ngan Kee et al., finding that
normalized CO at 5 minutes after spinal anesthesia to be greater within the
norepinephrine treatment group and Vallejo et al., 2017 finding no difference between
treatment groups. The definition of bradycardia was defined as a heart rate of <60 beats
per minute in all the studies except Sharkey et al., 2018 which defined it as a heart rate of
<50 beats per minute. Three of the five studies found the incidence of bradycardia to be
lower among the norepinephrine treatment group.
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Maternal incidence of intraoperative nausea and vomiting (N/V) between
treatment groups was analyzed among the five trials. Four of the five studies found no
statistical difference in rates of N/V between study groups. Vallejo et al., 2017 reported
incidence of nausea and vomiting separately and found that while rates of nausea were
similar between groups, the incidence of emesis was higher in the phenylephrine
intervention group.
Fetal Apgar scores at 1 minute and 5 minutes post delivery were collected in all
five trials. All five studies found that Apgar scores were similar between groups at both
assessments. Fetal umbilical cord gases were collected in all five trials. After applying
the data synthesis table no themes could be obtained between the studies regarding cord
gas analysis. Ngan Kee et al., 2015 found that UV pH was greater in the norepinephrine
treatment group (mean: 7.35), while Mohta et al., 2019 showed that UA pH was higher in
the phenylephrine treatment group (mean: 7.29). UV oxygen content was found to be
higher in only one study; Ngan Kee et al., in the norepinephrine intervention group.
Results from the five RCTs included in this systematic review demonstrated that
phenylephrine and norepinephrine had similar efficacy in the maintenance of maternal
blood pressure following spinal anesthesia. Overall, the incidence of bradycardia was
reduced among the norepinephrine group and heart rate was better maintained with
norepinephrine versus phenylephrine. The use of norepinephrine was accepted as a
possible alternative vasopressor in the obstetric setting but concluded that further
research is needed to assess the overall safety of norepinephrine.
Next, the summary and conclusion section will be discussed.
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Summary and Conclusions
Maternal hypotension is a common occurrence after the administration of spinal
anesthesia for cesarean delivery and if left untreated can be dangerous for both mother
and fetus. Maternal side effects of untreated hypotension can range from nausea and
vomiting, to unconsciousness and eventual cardiac arrest (Nagelhout et al., 2013).
Maternal hypotension can impact uteroplacental perfusion and potentially impact the
fetus by impairing maternal-fetal gas exchange (Stewart et al., 2010). The mainstay
treatment for maternal hypotension is phenylephrine, a direct-acting α1-adrenergic
agonist. However, stimulation of α1 receptors can cause a reflexive decrease in heart rate
and consequent decrease in cardiac output which theoretically could have a negative
impact on fetal wellbeing (Carvalho & Dyer, 2015; Ryu et al., 2019). Norepinephrine, a
vasopressor more commonly used in intensive care units, has α1-adrenergic agonist with
mild β1-agonist properties and can maintain blood pressure and heart rate, consequently
maintaining cardiac output (Nagelhout et al., 2013). The purpose of this paper was to
conduct a systematic review into the use of norepinephrine versus phenylephrine for the
treatment of maternal hypotension during spinal anesthesia for cesarean delivery.
Using the databases CINAHL, MEDLINE, Google Scholar and PubMed a
comprehensive literature review was conducted using search terms chosen by this author.
Many studies were found on the use of the vasopressors ephedrine or phenylephrine, but
the use of norepinephrine for treatment of maternal hypotension is a relatively new idea.
The lack of comprehensive literature highlighted the need for this systematic review.
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Utilizing inclusion and exclusion criteria, a total of 15 citations were screened
through the PRISMA checklist and flow diagram. The five included RCTs selected for
this systematic review were also analyzed using the CASP checklist to gauge the validity
and results found. Data was collected and organized into data collection tables, and a data
synthesis table. Outcomes assessed were maternal hypotension, rates of bradycardia,
effects on cardiac output, incidence of nausea vomiting, neonatal Apgar scores and
effects on umbilical cord gases. The efficacy of both drugs to maintain maternal blood
pressure and preserve heart rate was specifically compared.
All five studies found no difference between medication study groups in
rates of hypotensive episodes. Cardiac output was analyzed in two RCTs and resulting
data was conflicting; Ngan Kee et al., 2015 found normalized CO at 5 minutes was
greater in the norepinephrine group while Vallejo et al., 2017 found no variation between
groups. Three out of five studies found that norepinephrine preserved heart rate better
than phenylephrine. Maternal and neonatal outcomes were similar between study groups.
Only one study found that rates of vomiting were higher among the phenylephrine group,
while the other four studies found similar rates of nausea and vomiting between groups.
Fetal Apgar scores at 1 minute and 5 minutes were also found to be similar between
groups. Unfortunately, no pattern was found among umbilical cord gases; furthering the
argument for further study.
There were several limitations to this systematic review. Due to the novelty of the
use of norepinephrine in obstetrics, only five studies met inclusion criteria for this
systematic review. Among those selected there were variations in drug administration
methods, primary outcomes assessed and hemodynamic monitoring throughout the study.
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Further comprehensive research is indicated. Variations in dosage of medications also
made direct comparison difficult as well. Ngan Kee et al., 2015 used a potency ratio of
20:1 norepinephrine versus phenylephrine, yet Vallejo et al., 2017 used a potency ratio of
2:1. There was no consensus on true potency ratios between studies and further research
is warranted. Lastly a potential limitation was that only four databases were searched
which could have excluded potential research.
In summary, this systematic review shows that norepinephrine may be considered
a possible alternative for phenylephrine for the treatment of maternal hypotension
following spinal anesthesia during cesarean delivery. However, further research is
warranted into the safety and effects on umbilical cord gases before routine clinical
utilization.
Next, the recommendations and implications for advanced nursing practice will
be discussed.
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Recommendations and Implications for Advanced Nursing Practice
Certified Registered Nurse Anesthetists (CRNAs) provide anesthesia to women
undergoing cesarean deliveries every day across the nation. A hallmark of the CRNA’s
practice is the ability to adapt and advance their field by utilizing evidenced-based
research. While the occurrence of maternal hypotension is commonly occurring side
effect of spinal anesthesia, it can be mitigated and lessened with administration of
vasopressors. Administering the superior vasopressor can improve maternal and fetal
outcomes.
Phenylephrine is the current first line drug of choice for maternal hypotension, yet
as this systematic review demonstrated, it has a propensity to reduce heart rate.
Norepinephrine has similar ability to maintain blood pressure without depressing the
heart rate which could potentially maintain uteroplacental blood flow better then
phenylephrine. The alterations to cardiac output and subsequently uteroplacental blood
flow is likely more significant in compromised mothers or fetuses. As previously
mentioned, literature is scarce on the use of norepinephrine and the field could benefit
from more well-designed, large randomized control trials that include high risk patients.
Further study could also demonstrate appropriate potency and ideal method of
administration.
For the Advanced Practice Nurse, such as the CRNA, knowledge of the
medications administered is paramount for reduction in morbidity and mortality. As
discussed earlier, one of the concerns regarding norepinephrine is the risk of tissue
ischemia when peripherally administered. While the study by Medlej et al., (2017) did
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demonstrate the rate of complications to be very low, a limitation to their study was the
small sample size of 55 patients. Understanding risk mitigation strategies such as
utilizing a large bore IV placed in the antecubital fossa or through a central line is crucial
for the APRN. It should be noted that in the five selected studies for this systematic
review, none reported any complications from the peripherally administered
vasopressors. Further research is warranted into the rates of complications from
peripherally administrated norepinephrine and prior to any implementation of routine
clinical use, a hospital policy would have to be put in place to assure proper
administration.
Historically shifting clinician’s workflow and habits have been met with
resistance. Despite widespread evidence that phenylephrine was superior to the
previously first line agent, ephedrine, it took many years for systemic change and for
phenylephrine to be considered the ‘gold-standard.’ Even with the suggested continued
research into norepinephrine’s efficacy and safety within obstetrics, any changes to
practice should be anticipated to be met with hesitancy. Phenylephrine is a very
commonly used medication within the operating room and CRNAs are comfortable with
its medication profile while norepinephrine has been typically reserved for intensive care
and the cardiac anesthesia specialty. A lack of familiarity with norepinephrine could
increase the challenge to any change in practice (Carvalho & Dyer, 2015).
The use of norepinephrine over phenylephrine for the treatment of maternal
hypotension could have potential benefits to patient undergoing cesarean delivery,
especially patients who are already hemodynamically compromised. Further research
with randomized control trials with larger cohorts needs to be conducted prior to any
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widespread change to standards of practice. Continuing education on norepinephrine’s
dosages, side effects and risks should be implemented prior to use. Further research
should also be completed on the incidence of complications from peripherally
administered norepinephrine. Through furthering the research on the use of specific
vasopressors among the obstetric population, reductions to patient morbidity and
mortality can hopefully be made.
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Appendix B

Table B-1
Citation: Ngan Kee, W. D., Lee, S. W. Y., Ng, F. F., Tan, P. E., & Khaw, K. S. (2015). Randomized double-blinded comparison of
norepinephrine and phenylephrine for maintenance of blood pressure during spinal anesthesia for cesarean delivery. Anesthesiology, 122(4),
736-745. doi: 10.1097/ALN.0000000000000601.
Purpose: Compare
computer-controlled
infusions of
phenylephrine and
norepinephrine titrated
to maintain maternal
blood pressure in
parturients undergoing
spinal anesthesia
Setting/Sample: 104
patients enrolled at
Prince of Wales
Hospital, Hong Kong,
China. Inclusion
criteria was ASA status
I-II, singleton, term
pregnancy, and
scheduled elective
cesarean with routine
spinal anesthesia. 101
patients included in the
final study

Anesthesia
2.2 mL of
hyperbaric
bupivacaine
0.5% and
15mcg
fentanyl
injected
intrathecally
then the
patient was
placed in
supine
position.
Cohydration
of up to 2L of
Hartmann’s
solution was
given.

Intervention
Patients were randomized into
either the norepinephrine group or
phenylephrine group and received
infusions of either norepinephrine
5 mcg/mL (n=49) or
phenylephrine 100 mcg/mL (n=52)
administered via a closed loop
feedback computer system based
off hemodynamic parameters.
Maternal blood pressure and heart
rate were measured in 1-minute
intervals, CO, SVR and CI were
measured at 5-minute intervals.
Apgar scores were assessed 1
minute and 5 minutes after
delivery. Umbilical arterial and
venous blood were collected.

Outcomes
HR and CO averaged higher in the
norepinephrine group versus the
phenylephrine group. Systolic BP were
similar between groups. SVR was lower in
the norepinephrine group but there was no
difference in SV. Incidence of bradycardia
(HR <60 beats/min) was higher in the
phenylephrine group (55.8%, P <0.001)
versus norepinephrine (18.4%). Three
patients (6.1%) in the norepinephrine
group had nausea or vomiting versus two
patients (3.8%) in the phenylephrine group
(p=0.67).
Apgar scores at 1 and 5 minutes were
similar between groups. UV pH and UV
oxygen content were higher in the
norepinephrine group.

Limitations
CO was
measured via
suprasternal
doppler which
depends on an
estimate of
aortic valve
cross-sectional
area based of
patient’s height
which
introduces
potential for
systematic
error.
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Table B-2
Citation: Wang, X., Mao, M., Liu, S., Xu, S., Yang, J. (2019). A comparative study of bolus norepinephrine, phenylephrine, and ephedrine, for
the treatment of maternal hypotension in parturients with preeclampsia during cesarean delivery under spinal anesthesia. Medicine Science
Monitor, 25, 1093-1101. doi:10.12659/MSM.914143
Purpose: Compare
efficacy and safety of
bolus dose
norepinephrine,
phenylephrine and
ephedrine in parturient
women with
preeclampsia who had
hypotension following
spinal anesthesia for
cesarean delivery.
Setting/Sample: 315
patients in Nanjing,
China. Inclusion was
ASA I or II, singleton,
non-laboring,
scheduled for spinal
anesthesia, and
diagnosed with preeclampsia (BP
≥140/90) or severe
pre-eclampsia (BP
≥160/110).

Anesthesia
2.0-2.2mL of
hyperbaric
bupivacaine
0.5% injected
intrathecally
while the
patient was in
left lateral then
placed into
supine position
after
completion.
Ringer’s
Lactate was
infused at a
maximum rate
of 10ml/kg.

Intervention
Patients were randomized into
either the norepinephrine group
(n=56), the phenylephrine group
(n=55), or the ephedrine group
(n=55).
Maternal blood pressure and heart
rate were measured in 1-minute
intervals from intrathecal
injection until delivery. Maternal
complications such as nausea,
vomiting, dizziness and shivering
were also recorded.
Apgar scores were assessed 1
minute and 5 minutes after
delivery. Umbilical arterial blood
gas and pH was analyzed.

Outcomes
The standardized HR over time was higher
in the norepinephrine group then the
phenylephrine. Norepinephrine had a lower
incidence of tachycardia (HR >120) then
ephedrine (16.1 vs. 36.4%, 95% CI,) and a
lower incidence of bradycardia (HR <60)
then phenylephrine (3.6% vs. 21.8%, 95%
CI). Incidence of IONV, dizziness and
shivering were similar between
norepinephrine and phenylephrine.
Apgar and umbilical artery blood gas
between the norepinephrine and
phenylephrine groups were not significantly
different.

Limitations
Uterine arterial
blood flow was
not measured
to see the
effects of
vasopressors on
uteroplacental
perfusion. All
factors that can
increase IONV
beyond BP
were not
assessed.
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Table B-3
Citation: Vallejo, M. C., Attallah, A. F., Elzamzamy, O. M., Cifarelli, D.T., Phelps, A. L., Hobbs, G. R., … Ranganathan, P. (2017). An openlabel randomized controlled clinical trial for comparison of continuous phenylephrine versus norepinephrine infusion in prevention of spinal
hypotension during cesarean delivery. International Journal of Obstetric Anesthesia, 29, 18-25. doi:10.1016/j.ijoa.2016.08.005
Purpose: Compare
prophylactic, fixed-rate
intravenous infusion of
phenylephrine and
norepinephrine during
cesarean delivery under
spinal anesthesia.
Setting/Sample: 85
patients from 8/20148/2015 in West Virginia.
Inclusion was ASA <3,
singleton gestation, >36
weeks, scheduled elective
CD under spinal anesthesia.
Exclusion was hypertensive
disease, preeclampsia,
eclampsia, use of cardiac
medication or medication
for blood pressure control,
previous gastric bypass,
history of chronic opioid
use, BMI >40, emergency
CD, history of seizures and
progressive neurologic
disease.

Anesthesia
12-15mg
hyperbaric
anesthesia,
preservativefree morphine
0.2mg and
fentanyl
20mcg. Ringers
Lactate
solution 500mL
was
administered
over 15
minutes prior
to spinal
anesthesia

Intervention
Patients were randomized
into the phenylephrine group
(n=38), or the
norepinephrine group
(n=43). Four patients were
excluded from the
norepinephrine group
because of monitoring
equipment failure, or
emergency cesarean
delivery. The phenylephrine
group received 100 mcg/mL
infused at 0.1 mcg/kg/min
and the norepinephrine
group received 0.05
mcg/kg/min to maintain SBP
within 100-120% of
baseline. Rescue boluses of
100mcg of phenylephrine
were administered if BP fell
below 100% of baseline.
Rescue boluses of ephedrine
were given for bradycardia
(HR <60).

Outcomes
There were no differences between the
two groups in infusion duration,
incidence of bradycardia or incidence
of nausea, but the incidence of emesis
was greater in the phenylephrine group
(Group P=26.3%, Group N=16.3%).
The proportion of patients who
received ≥ 1 rescue phenylephrine
dose was similar between groups
(Group P=52.6% vs. Groups
N=46.5%). The proportion of patients
who received ≥1 bolus of rescue
ephedrine was greater in the
phenylephrine group (Group P: 23.7%
vs. Group N: 2.3%)
There was no difference between
groups in the proportion of Apgar
scores <7 at 1 minute and 5 minutes or
in umbilical venous cord blood gases.
No significant differences in HR, Co,
CI, SV and/or SVR were found.

Limitations
High rates of nausea
and vomiting could
be attributed to
intrathecal morphine
and fentanyl. The
study was unblinded
which could have
led to bias. Another
limitation is that the
fixed-rate infusion
of phenylephrine
was low (about
8mcg/min in an 80
kg woman) which is
lower than most
current regimens.
High incidences of
nausea and vomiting
could presumably
due to low rates of
phenylephrine.
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Table B-4
Citation: Sharkey, A. M., Siddiqui, N., Downey, K., Ye, X. Y., Guevara, J., Carvalho, J. C. A.. (2018). Comparison of intermittent intravenous
boluses of phenylephrine and norepinephrine to prevent and treat spinal-induced hypotension in cesarean deliveries: randomized controlled
trial. Anesthesia & Analgesia, 129(5), 1312-1318. doi:10.1213/ANE.0000000000003704
Purpose: To compare
norepinephrine and
phenylephrine efficacy when
used as intermittent bolus
regimens to prevent and treat
spinal-induced hypotension.
Sample/Setting: 112 women
were enrolled at Mount Sinai
Hospital in Toronto, ON, Canada
from 1/3/2017-4/17/17.
Inclusion criteria was elective csection under spinal anesthesia,
ASA status ≤III, ≥18 years of
age, singleton pregnancy, ≥36week gestation, body weight 50100kg and height 150-180cm.
Exclusion was
allergy/hypersensitivity to
norepinephrine or
phenylephrine, pregnancy
induced hypertension,
cardiovascular or
cerebrovascular disease, fetal
abnormalities, history of diabetes
and patient refusal.

Anesthesia
13.5 mg of
0.75%
hyperbaric
bupivacaine
with 10mcg of
fentanyl and
100mcg
morphine.
Coloaded with
10mL/kg of
Ringers Lactate
solution to a
maximum of 1L.

Intervention
Patients were randomized
into the phenylephrine
group (n=56), or the
norepinephrine group
(n=56). Patients were
bloused with either
6mcg/mL of norepinephrine
or 100mcg/mL of
phenylephrine depending
on group allocation.
Hypotension was defined as
SBP <80% baseline.
Ephedrine 10mg was rescue
medication in both groups
if SBP was below baseline
and HR was <60 bpm.

Outcomes
Incidence of bradycardia (HR <50
bpm) were lower in the
norepinephrine group (10.9% versus
37.5%). Pts in the phenylephrine
group were at a higher risk of
multiple episodes of bradycardia
versus the norepinephrine group.
There was no difference in rates of
hypotension between groups.
Patients requiring rescue boluses of
ephedrine were higher in the
phenylephrine group (21.4% versus
7.2%) There was no difference
between the groups in incidence of
hypertension, tachycardia, nausea, or
vomiting.
No difference was found in fetal
Apgar scores at 1 and 5 minutes or in
umbilical cord blood gases.

Limitations
HR was used as a
surrogate marker
of cardiac output
and was not
directly
measured.
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Table B-5
Citation: Mhota, M., Garg, A., Chilkoti, G. T., Malhotra, R. K.. (2019). A randomized controlled trail of phenylephrine and noradrenaline
boluses for treatment of postspinal hypotension during elective caesarean section. Association of Anaesthestists, 74, 850-855.
doi:10.111/anae.14675
Purpose: Compare the
efficacy, safety, sideeffect profile and
neonatal outcome after
phenylephrine and
norepinephrine
administration.
Sample/Setting: 90
women were included
from December 2016January 2018 in Delhi,
India. Inclusion criteria
was an uncomplicated,
singleton elective csection with spinal
anesthesia. Exclusion
criteria was preexisting
medical conditions,
placenta previa, fetal
malformations, systolic
arterial pressure <100
mmHg or fetal weight
extremes. The
investigators and the
patients were blinding to
medication administered.

Anesthesia
2.2 ml
hyperbaric 0.5%
bupivacaine, or
2mL if patient
was <150cm in
height. Patients
were coloaded
with 15mL/kg of
Ringer’s Lactate
solution.

Intervention
Patients were randomized into
either the phenylephrine group
(n=45) or the norepinephrine
group (n=45). Hypotension
was defined as a decrease of
≥20% from baseline systolic
blood pressure or a decrease
below 100 mmHg systolic
blood pressure. Bradycardia
was defined as a heart rate of
less than 60 beats per minute
with 0.6 mg IV of atropine
being the rescue medication
for a heart rate less than 45
beats per minute. For
hypotensive episodes, a series
of 1-mL bolus of either 100
mcg/mL of phenylephrine or 5
mcg/mL of norepinephrine
were administered until blood
pressures were corrected.

Outcomes
The primary outcome measured was
incidence of maternal bradycardia after
medication administration. Incidence of
bradycardia were higher in the
phenylephrine group (37.8%) versus the
norepinephrine group (22.2%). No
differences were found in the number of
hypotensive periods; however, the total
number of boluses were higher in the
phenylephrine group (median dose 200mcg)
versus the norepinephrine group (median
dose 5mcg). The mean heart rate 1 minute
after study drug administration was lower in
the phenylephrine group (76.8 beats/min)
versus the norepinephrine group (88.3
beats/min). There were no differences in the
incidence of nausea, vomiting nor dizziness.
Fetal umbilical blood gases were found to
be significantly higher in the phenylephrine
group verses the norepinephrine group.
There was no significant difference in
Apgar scores at 1 minute or 5 minutes.

Limitations
The study
used a dose
ration of 1:20
for both
norepinephrin
e and
phenylephrine
which recent
studies have
suggested that
those doses
are not
equipotent.
Sample size
was also
smaller for
this study
which may
have affected
the true
difference in
incidence of
bradycardia
between
groups.
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Appendix C
Critical Appraisal Skills Program (CASP) tables
Table C-1
Citation: Ngan Kee, W. D., Lee, S. W. Y., Ng, F. F., Tan, P. E., & Khaw, K. S. (2015).
Randomized double-blinded comparison of norepinephrine and phenylephrine for maintenance
of blood pressure during spinal anesthesia for cesarean delivery. Anesthesiology, 122(4), 736745. doi: 10.1097/ALN.0000000000000601.
Question

Yes

Did the trial address a clearly focused issue?

✔

Was the assignment of patients to treatments randomized?

✔

Were all of the patients who entered the trial properly accounted for at its
conclusion?

✔

Were patients, health workers and study personnel ‘blind’ to treatment?

✔

Were the groups similar at the start of the trial?

✔

Aside from the experimental intervention, were the groups treated equally?

✔

How large was the treatment effect? The primary outcomes assessed were HR
and CO. A varied number of blood pressure and HR measurements were recorded
due to the varying time for each measurement. Cardiac output was recorded a
minimal of four times for each patient.

✔

How precise was the estimate of the treatment effect? The authors calculated
that a sample size of 47 patients per group would have greater than 90% power to
detect a 20% difference in cardiac output between groups. To allow for study
dropouts the sample size was increased by 5% with a goal of 52 patients per group.

✔

Can’t No
Tell

✔

Can the results be applied to the local population, or in your context?
Were all clinically important outcomes considered?

✔

Are the benefits worth the harms and costs?

✔
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Table C-2
Citation: Wang, X., Mao, M., Liu, S., Xu, S., Yang, J. (2019). A comparative study of bolus
norepinephrine, phenylephrine, and ephedrine, for the treatment of maternal hypotension in
parturients with preeclampsia during cesarean delivery under spinal anesthesia. Medicine Science
Monitor, 25, 1093-1101. doi:10.12659/MSM.914143

Question

Yes

Did the trial address a clearly focused issue?

✔

Was the assignment of patients to treatments randomized?

✔

Were all of the patients who entered the trial properly accounted for at its
conclusion?

✔

Were patients, health workers and study personnel ‘blind’ to treatment?

✔

Were the groups similar at the start of the trial?

✔

Aside from the experimental intervention, were the groups treated equally?

✔

How large was the treatment effect? The primary outcome was overall maternal SBP
and HR, secondary outcomes were incidence of tachycardia, bradycardia and
hypertension.

✔

How precise was the estimate of the treatment effect? Using a pilot study as
reference, a minimum of 49 cases per group was needed to detect statistically
significant differences in maternal tachycardia. The sample size for this study was
increased to 55 in each group to account for drop out.

✔

Can the results be applied to the local population, or in your context?

✔

Were all clinically important outcomes considered?

✔

Are the benefits worth the harms and costs?

✔

Can’t
Tell

No
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Table C-3
Citation: Vallejo, M. C., Attallah, A. F., Elzamzamy, O. M., Cifarelli, D.T., Phelps, A. L.,
Hobbs, G. R., … Ranganathan, P. (2017). An open-label randomized controlled clinical trial for
comparison of continuous phenylephrine versus norepinephrine infusion in prevention of spinal
hypotension during cesarean delivery. International Journal of Obstetric Anesthesia, 29, 18-25.
doi:10.1016/j.ijoa.2016.08.005
Question

Yes

Did the trial address a clearly focused issue?

✔

Was the assignment of patients to treatments randomized?

✔

Were all of the patients who entered the trial properly accounted for at its
conclusion?

✔

Can’t
Tell

No

✔

Were patients, health workers and study personnel ‘blind’ to treatment?
Anesthesia providers were made aware of the study drug selected upon patient entering
the operating room.
Were the groups similar at the start of the trial?

✔

Aside from the experimental intervention, were the groups treated equally?

✔

How large was the treatment effect? The primary endpoint was the number and total
dose of rescue bolus interventions needed to maintain SBP. Incidence of N/V,
bradycardia, Apgar scores were also compared using the chi-square test.

✔

How precise was the estimate of the treatment effect? A local pilot study was
assessed and based off power analysis 35 patients were required per group to detect a
reduction to 10% of the incidence of hypotension at the 0.05 significance level with
80% power.

✔

✔

Can the results be applied to the local population, or in your context?
Were all clinically important outcomes considered?

✔

Are the benefits worth the harms and costs?

✔
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Table C-4
Citation: Sharkey, A. M., Siddiqui, N., Downey, K., Ye, X. Y., Guevara, J., Carvalho, J. C. A..
(2018). Comparison of intermittent intravenous boluses of phenylephrine and norepinephrine to
prevent and treat spinal-induced hypotension in cesarean deliveries: randomized controlled trial.
Anesthesia & Analgesia, 129(5), 1312-1318. doi:10.1213/ANE.0000000000003704
Question

Yes

Did the trial address a clearly focused issue?

✔

Was the assignment of patients to treatments randomized?

✔

Were all of the patients who entered the trial properly accounted for at its
conclusion?

✔

Were patients, health workers and study personnel ‘blind’ to treatment?

✔

Were the groups similar at the start of the trial?

✔

Aside from the experimental intervention, were the groups treated equally?

✔

How large was the treatment effect? The primary outcome was the incidence of any
maternal bradycardia. Secondary outcomes included the incidence of hypotension,
hypertension, tachycardia, N/V and umbilical gases and Apgar scores.

✔

How precise was the estimate of the treatment effect? Sample size was based of 2
previous studies done by the authors group. A sample size of 56 patients per group
would have an 80% power to detect a 70% relative decrease in incidence of
bradycardia.

✔

Can the results be applied to the local population, or in your context?

✔

Were all clinically important outcomes considered?

✔

Are the benefits worth the harms and costs?

✔

Can’t
Tell

No

56

Table C-5
Citation: Mhota, M., Garg, A., Chilkoti, G. T., Malhotra, R. K.. (2019). A randomized
controlled trail of phenylephrine and noradrenaline boluses for treatment of postspinal
hypotension during elective caesarean section. Association of Anaesthestists, 74, 850-855.
doi:10.111/anae.14675
Question

Yes

Did the trial address a clearly focused issue?

✔

Was the assignment of patients to treatments randomized?

✔

Were all of the patients who entered the trial properly accounted for at its
conclusion?

✔

Were patients, health workers and study personnel ‘blind’ to treatment?

✔

Were the groups similar at the start of the trial?

✔

Aside from the experimental intervention, were the groups treated equally?

✔

How large was the treatment effect? The primary goal was to assess the incidence of
maternal bradycardia after study drug administration. Secondary outcomes were blood
pressure, vasopressor requirements, maternal complications, and neonatal outcomes.

✔

How precise was the estimate of the treatment effect? Utilizing information from a
previously done study, a sample size of 45 patients was required using one-sided,
two=proportion z-test method with pooled variance, with a power of 80% at a 5%
significance level.

✔

Can the results be applied to the local population, or in your context?

✔

Were all clinically important outcomes considered?

✔

Are the benefits worth the harms and costs?

✔

Can’t
Tell

No

57

Appendix D
Data Synthesis Table

Author,
Year

ASA
Classification &
Patient
Characteristics

Incidence of Maternal
Hypotension

Maternal Cardiac
Output

Incidence of
Bradycardia

Incidence of
intraoperative
nausea/vomiting

Neonatal
Apgar Scores

Umbilical Cord
Gases

Ngan Kee et
al., 2015

ASA I-II, ≥18
years old,
singleton, nonlaboring, term
pregnancies
scheduled for
elective cesarean
section.

(Defined as SBP <80%
baseline) SBP was
maintained similarly
between groups (P=0.36)

Normalized CO at 5
minutes was greater
in the N group
(median 102.7%
[94.3-116.7%]
versus P group
(93.8% [85.0103.1%]) (p=0.004)

(Defined as HR <60
bpm). Lower in the
N group (18.4%)
versus P group
(55.8%, p<0.001)

No statistical
difference was found
between groups in
rates of N/V (Group
N n=3, 6.1%; Group P
n=2, 3.8%; P=0.67).

Apgar scores for
both groups
were greater
than 7 at 1
minute and 5
minutes.
Average scores
were not
recorded.

Wang et al.,
2019

ASA I-II,
singleton, nonlaboring,
scheduled for
spinal
anesthesia.
Parturients were
diagnosed with
pre-eclampsia
(BP ≥140/90

(Defined as SBP <80%
of baseline) No statistical
difference was found in
overall SBP over time
between groups (Group
N 125.1 ±8.5, group P
124.2±6.6, group E
123.1±6.8).
The number of
hypotensive episodes

(Defined as HR <60
bpm) Lower in
group N (3.6%)
versus group P
(21.8%) (P=0.004)

Rates of nausea in
group N were (3.5%),
group P (5.5%), and
group E (9.1%). Rates
of vomiting in group
N were (1.8%), group
P (1.8%) and group E
(11%). Overall
combined N/V rates
were slightly less in

Apgar scores
were similar
among the
groups. No
Apgar score was
<9 at 5 minutes

UA pH was similar
between groups; N
group (7.30 [7.287.33]) and P group
(7.29 [7.28-7.32])
P=0.45). UA PCO2
was similar between
groups; group P (52
[48-56]), Group P
(50 [48-56])
(P=0.77)
UV pH was greater
in group N (7.35
[7.34-7.37]) vs P
group (7.34 [7.327.36]) (P=0.031)
UV oxygen content
was higher in group
N (12.7 [11.3-14.4])
vs group P (11.8
[9.6-13.7])
(P=0.047)
No differences were
found in UA blood
gases from group N
and group P. UA pH
was higher in group
N (7.32 ±0.02) vs
group E (7.31±0.03)
(P=0.006). UA
lactate was lower in
group N (1.3±0.3)
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with 24 hour
proteinuria ≥300
mg or ≥1+ with
dipstick)
ASA <3,
singleton, >36
week scheduled
elective cesarean
delivery

ASA ≤III, ≥18
years of age,
singleton
pregnancy >36
weeks gestation,
patient weight
50-100kg, and
height 150180cm

was statistically
insignificant between
groups.
(Defined as an SBP
decrease <100% of
baseline) Incidence of
hypotension were treated
with recue boluses of
phenylephrine and/or
ephedrine (given for
hypotension with
bradycardia). The groups
were similar in who
received ≥1 vasopressor
bolus (Group P 65.8%
[n=25] vs Group N:
46.5% [n=21], P=0.12).
The incidence one or
more phenylephrine
rescue boluses were
similar (Group P: 52.6%
[n=20] vs. group N:
46.5% [n=20], P=0.58).
The incidence of ≥1
ephedrine bolus was
greater in group P
(23.7%, [n=9]) vs group
N (2.3%, [n=1])
(P=<0.01)
(Defined as an SBP
<80% of baseline value)
Rates of hypotension
were similar between the
two groups (group N
38% vs group P 39%,
P=0.9). The incidence of
patients requiring rescue
boluses of ephedrine for
2 consecutive SBP <80%
of baseline with or
without a HR <60bpm
were lower in group N
(7.2%) vs group P
(21.4%)

No significant
differences were
found in CO
between groups
(P=0.5)

(Defined as a HR
<60 bpm) The
incidence of
bradycardia was
similar between
groups (group P:
23.7% vs group N:
18.6%, P=0.58)

(Defined as an HR
<50 bpm) Rates of
bradycardia were
lower in group N
(10.9%) versus
group P (37.5%)
(P=<0.001)

group N (5.4%)
versus group P (7.3%)
and group E (20%)
(P=0.02).
All patients received
prophylactic
ondansetron 4mg after
delivery of the baby.
Incidence of nausea
was similar between
groups (Group P
63.2% vs group N
51.2%, P=0.28). The
incidence of emesis
was greater in group P
(26.3%) vs group N
(16.3%) (P<0.001)

Incidences of nausea
and vomiting were
similar between
groups. Group P
(32.1% and 7.1%) vs
group N (27.3% and
1.8%) (P=0.57 and
P=0.17) respectively.

vs group E (1.8±0.5)
(P=<0.001)
Apgar scores <7
at 1 minute were
similar between
groups (Group
P=6 vs group
N=6, P=0.82).
Apgar scores <7
at 5 minutes
were also
similar (Group
P=2 vs group
N=1, P=0.48)

UV were only
obtained if clinically
indicated.
UV pH were similar
between groups
(Group N 7.30
[n=5] vs group N
7.27 [n=7], P=0.42)

Apgar scores at
1 and 5 minutes
were >7 in all
cases. No
difference was
found between
groups.

No difference was
seen in umbilical
cord blood gases
between groups
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Uncomplicated,
singleton
pregnancies.
Women with
comorbid
medical
conditions or
fetal
compromise
were excluded.

(Defined as a decrease of
≥20% from baseline SBP
or an absolute value
<100 mmHg). No
statistical difference was
found between the
groups in number of
hypotensive episodes, or
the number of boluses to
treat the first episode of
hypotension.
Hypotensive episodes
group P (n=2) vs group
N (n=1), (P=0.06). The
total number of
vasopressor boluses
required to treat
hypotensive episodes
was higher in group P
than group N (P=0.01).

(Defined as a HR of
<60 bpm) The
incidence of
bradycardia in group
P was 37.8% verses
group N 22.2%
(P=0.17). Rescue
doses of atropine
were required in
group P 6.6% (n=3)
and group N 2.2%
(n=1) (P=0.10).
Mean HR at 1
minute after
vasopressor
administration was
higher in group N
(88.3 bpm) vs group
P (76.8 bpm).

No statistical
significance between
groups in rates of
nausea or vomiting.
(P=1.0)

Apgar scores at
1 and 5 minutes
were >7 in all
cases. No
difference was
found between
groups.

UA/UV pH,
bicarbonate, and
base excess were
higher in group P vs
group N. UA pH
group P (mean:
7.29) vs group N
(7.25), (P=0.03).
UA pCO2 group P
(52.2) vs group N
(53.7). (P=0.52).
Rates of neonatal
acidosis (UA pH
<7.2) in group P
(15.6%, n=7) vs
group N (13.3%,
n=6) (P=0.77)

